Tonix Pharmaceuticals: Canaccord Genuity initiates coverage with buy rating; target price $18
TNXP•Canaccord Genuity initiated coverage of Tonix Pharmaceuticals with a buy rating and an $18 target price.
Related News
Nasdaq trade halt: volatility trading pause at 09:30 am
XP•
HSBC cuts global equities to 'neutral' on Middle East, AI risks
HSBC•
S&P Dow Jones names Kalshi preferred prediction market platform for index event contracts
SPGI•
Sophos forecasts industry-wide incident response capacity crunch as cyberattacks rise
XLK•
Incyte partners with Bristol Myers Squibb on pancreatic cancer combination trial
INCY•